<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9046">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02989168</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-026</org_study_id>
    <nct_id>NCT02989168</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest</brief_title>
  <acronym>Zephyr</acronym>
  <official_title>A Phase II Open Label Study to Evaluate the Effect of GBT440 on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Who Are Using Supplemental Oxygen at Rest (ZEPHYR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <brief_summary>
    <textblock>
      This is an open label study in which eligible IPF subjects who are using supplemental oxygen
      at rest will receive GBT440 orally daily.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in oxygen saturation at end of treatment period compared to baseline</measure>
    <time_frame>Days 1 to 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in supplemental oxygen requirement at end of treatment period compared to baseline</measure>
    <time_frame>Days 1 to 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of GBT440 on performance of the 6MWT</measure>
    <time_frame>Days 1 to 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of GBT440 on IPF related symptoms using patient related outcomes</measure>
    <time_frame>Days 1 to 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate pulmonary function using pulmonary function tests</measure>
    <time_frame>Days 1 to 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Days 1 to 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentration of GBT440</measure>
    <time_frame>Days 1 to 120</time_frame>
    <description>Cmin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>GBT440 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GBT440</intervention_name>
    <arm_group_label>GBT440 Dose 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of IPF.

          -  Receiving supplemental oxygen for use at rest.

          -  Weight â‰¥ 40 kg.

          -  Male or female of child bearing potential willing and able to use highly effective
             methods of contraception from study start to 30 days after the last dose of study
             drug.

        Exclusion Criteria:

          -  FEV1/FVC &lt; 70%

          -  History of other interstitial lung diseases.

          -  Subject plans to begin or has commenced pulmonary rehabilitation within 30 days of
             screening.

          -  Corticosteroid (&gt; 10 mg per day of prednisone or an equivalent) administered for 7
             days or longer, within 30 days of screening.

          -  Participated in another clinical trial of an investigational drug (or medical device)
             within 30 days or 5-half-lives, whichever is longer, prior to screening, or is
             currently participating in another trial of an investigational drug (or medical
             device).

          -  Female who is breast-feeding or pregnant

          -  Current smoker or history of smoking within 3 months from screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicholas Vlahakis, M.D.</last_name>
    <phone>650-741-7730</phone>
    <email>nvlahakis@globalbloodtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharonda Keazor</last_name>
      <phone>205-975-8335</phone>
      <email>skeazor@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cori Fratelli</last_name>
      <phone>303-388-4461</phone>
      <email>fratellic@njhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy M. Ditta</last_name>
      <phone>504-988-4040</phone>
      <email>sditta@tulane.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Johnson</last_name>
      <phone>215-707-4679</phone>
      <email>Sylvia.Johnson@tuhs.temple.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Del Greco</last_name>
      <phone>615-343-7068</phone>
      <email>james.del.greco@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Sweeten</last_name>
      <email>Scott.Sweeten@hsc.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 7, 2016</lastchanged_date>
  <firstreceived_date>November 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic pulmonary fibrosis</keyword>
  <keyword>hypoxemia</keyword>
  <keyword>oxygen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
